Genome sequencing has revolutionized the diagnosis of genetic diseases. Close collaborations between basic scientists and clinical genomicists are now needed to link genetic variants with disease causation. To facilitate such collaborations, we recommend prioritizing clinically relevant genes for functional studies, developing reference variant-phenotype databases, adopting phenotype description standards, and promoting data sharing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511379 | PMC |
| http://dx.doi.org/10.1016/j.cell.2017.03.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Glycyrrhizic acid-based multifunctional nanoplatform for tumor microenvironment regulation.
Chin J Nat Med
December 2024
State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy School, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China. Electronic address:
Natural compounds demonstrate unique therapeutic advantages for cancer treatment, primarily through direct tumor suppression or interference with the tumor microenvironment (TME). Glycyrrhizic acid (GL), a bioactive ingredient derived from the medicinal herb Glycyrrhiza uralensis Fisch., and its sapogenin glycyrrhetinic acid (GA), have been recognized for their ability to inhibit angiogenesis and remodel the TME.
View Article and Find Full Text PDFA Multiform Heterogeneity Framework for Alzheimer's Disease Based on Multimodal Neuroimaging.
Biol Psychiatry
December 2024
School of Artificial Intelligence, Beijing University of Posts and Telecommunications, Beijing, China; Brainnetome Center, Institute of Automation, Chinese Academy of Sciences, Beijing, China. Electronic address:
Understanding the heterogeneity of Alzheimer's disease (AD) is crucial for advancing precision medicine specifically tailored to this disorder. Recent research has deepened our understanding of AD heterogeneity, yet translating these insights from bench to bedside via neuroimaging heterogeneity frameworks presents significant challenges. In this review, we systematically revisit prior studies and summarize the existing methodology of data-driven neuroimaging studies for AD heterogeneity.
View Article and Find Full Text PDFBiophysical Analysis of Therapeutic Antibodies in the Early Development Pipeline.
Biologics
December 2024
School of Molecular and Cellular Biology, Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK.
The successful progression of therapeutic antibodies and other biologics from the laboratory to the clinic depends on their possession of "drug-like" biophysical properties. The techniques and the resultant biophysical and biochemical parameters used to characterize their ease of manufacture can be broadly defined as developability. Focusing on antibodies, this review firstly discusses established and emerging biophysical techniques used to probe the early-stage developability of biologics, aimed towards those new to the field.
View Article and Find Full Text PDFMitochondrial-targeted therapies in traumatic brain injury: From bench to bedside.
Neurotherapeutics
December 2024
Novel Treatments for Acute Brain Injury Institute, Texas Medical Center, TX, USA; Department of Neurosurgery, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA. Electronic address:
Traumatic brain injury (TBI) is a leading cause of morbidity and mortality worldwide, with limited effective therapeutic options currently available. Recent research has highlighted the pivotal role of mitochondrial dysfunction in the pathophysiology of TBI, making mitochondria an attractive target for therapeutic intervention. This review comprehensively examines advancements in mitochondrial-targeted therapies for TBI, bridging the gap from basic research to clinical applications.
View Article and Find Full Text PDFThrombosis, Translational Medicine, and Biomarker Research: Moving the Needle.
J Am Heart Assoc
December 2024
Cardiovascular Research Institute Maastricht, Maastricht University Maastricht Netherlands.
Arterial and venous thromboembolism are leading causes of morbidity and death worldwide. Despite significant advances in the diagnosis, prognostication, and treatment of thrombotic diseases over the past 3 decades, the adoption of findings stemming from translational biomarker research in clinical practice remains limited. Biomarkers provide an opportunity to enhance our understanding of pathophysiological processes and optimize treatment strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!